Trifecta of clinical stage biotechs unveil IPO plans, braving Wall Street's coronavirus panic

Coronavirus fears precipitated a rout on global stock prices on Monday, but three clinical-stage biotechs are soldiering on with plans to make public debuts. The biggest is Zentalis Pharmaceuticals — which is gunning for a $100 million IPO, three months after an $85 million round of financing.